Apellis Pharmaceuticals Inc. has announced new one-year data from the open-label period of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The results, which will be presented at the upcoming American Society of Nephrology (ASN) Kidney Week, indicate that EMPAVELI achieved significant and sustained reductions in proteinuria, regardless of immunosuppressant use or baseline proteinuria levels. Complete proteinuria remission (UPCR ≤0.5 g/g) was sustained through one year in one-third of patients. In two indirect treatment comparisons with published data from the Phase 3 APPEAR-C3G trial of iptacopan, EMPAVELI was found to be superior in reducing proteinuria and achieving the composite renal endpoint in patients with C3G. The analyses used both the Bucher method and a matching-adjusted indirect comparison (MAIC) to account for trial differences.